Stockscreener 앱 받기
5.13
0.39%
0.02
시간 외 거래:
5.18
0.05
+0.97%
Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스
Atossa Therapeutics Appoints Two New Medical Directors in Breast Oncology and Rare Diseases - Contract Pharma
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology - GlobeNewswire Inc.
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives - PR Newswire
Should I set a stop loss on Atossa Therapeutics Inc2026 Decliners & Growth Focused Stock Pick Reports - baoquankhu1.vn
Atossa Therapeutics announces launch of early-stage DMD program for rare disease awareness - Traders Union
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference - Sahm
Atossa presents preclinical data on endoxifen for muscular dystrophy - Investing.com South Africa
Atossa presents preclinical data on endoxifen for muscular dystrophy By Investing.com - Investing.com Australia
Atossa Therapeutics, Inc. Presents Clinical Trial Update On Z-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference - marketscreener.com
Atossa Therapeutics shares clinical trial update for Z-endoxifen at MDA conference - Traders Union
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference – Company AnnouncementFT.com - Financial Times
Big Money Moves: Is Atossa Therapeutics Inc a potential multi bagger2026 Price Swings & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Muscle biomarker improvement reported in dystrophic mice, Atossa Therapeutics asserts - Traders Union
Is Atossa Therapeutics Inc likely to announce a buybackJuly 2025 Momentum & Reliable Entry Point Alerts - baoquankhu1.vn
Hedge Fund Moves: Is Atossa Therapeutics Inc stock undervalued right nowJuly 2025 EndofMonth & Long-Term Safe Return Strategies - baoquankhu1.vn
CEO Moves: Is Atossa Therapeutics Inc a speculative investmentQuarterly Market Summary & Smart Swing Trading Alerts - baoquankhu1.vn
Cash from operating activities of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Cash from financing activities of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Free cash flow of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Aug Fed Impact: Is Atossa Therapeutics Inc stock undervalued right nowQuarterly Profit Summary & Daily Growth Stock Investment Tips - baoquankhu1.vn
Total liabilities & shareholders' equities of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Atossa Therapeutics advances Z-endoxifen platform in oncology and DMD targeting molecular precision - Traders Union
ATOS PE Ratio & Valuation, Is ATOS Overvalued - Intellectia AI
Is Atossa Therapeutics Inc. stock influenced by commodity pricesJuly 2025 Recap & Daily Profit Focused Screening - mfd.ru
ATOS Should I Buy - Intellectia AI
ATOS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Atossa Therapeutics outlines Z-Endoxifen strategy for breast cancer prevention - Traders Union
Atossa Therapeutics Launches New $50 Million ATM Program - The Globe and Mail
Atos (ATOS) cuts $100M Jefferies ATM to $0, effective Feb 20, 2026 - Stock Titan
Atossa Genetics Inc. (NASDAQ:ATOS) Receives $95.00 Consensus PT from Analysts - Defense World
Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk - The Globe and Mail
Net debt of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Patterns Watch: What is Atossa Therapeutics Incs TAM Total Addressable Market2025 Breakouts & Breakdowns & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Atossa Therapeutics, Inc. Balance Sheet – MUN:YAG - TradingView
Atossa Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Atossa Therapeutics to Participate in UCSF women health event - Traders Union
Basic earnings per share (basic EPS) of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Atossa Therapeutics: Key Developments and Upcoming Catalysts - AD HOC NEWS
Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 29.7% in January - Defense World
Is Atossa Therapeutics Inc. likely to announce a buybackJuly 2025 Rallies & Weekly Breakout Watchlists - mfd.ru
Is Atossa Therapeutics Inc. a speculative investmentWeekly Market Report & Free Technical Pattern Based Buy Signals - mfd.ru
Jobs Data: Is Atossa Therapeutics Incs growth already priced inJuly 2025 Price Swings & Stepwise Swing Trade Plans - baoquankhu1.vn
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook - The Malaysian Reserve
Atossa Therapeutics issues letter to shareholders highlighting 2025 accomplishments and 2026 outlook - marketscreener.com
Atossa Therapeutics Issues 2026 Outlook and Strategic Update - TipRanks
Atossa Therapeutics Issues Letter To Shareholders Highlighting 2025 Accomplishments And 2026 Outlook - TradingView
Atossa Therapeutics Issues 2026 Shareholder Letter Highlighting Key Developments - TradingView
Can Atossa Therapeutics Inc. be recession proofJuly 2025 Momentum & Community Consensus Trade Signals - mfd.ru
Atossa Therapeutics launches research program for oral therapy in DMD - Traders Union
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS) and Agilon Health (AGL) - The Globe and Mail
We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth Carefully - Yahoo Finance
Market Outlook: Is Atossa Therapeutics Inc part of any ETFWeekly Trading Summary & Weekly Momentum Picks - baoquankhu1.vn
Cash from financing activities of Atossa Therapeutics, Inc. – GETTEX:YAG - TradingView
Cost of goods sold of Atossa Therapeutics, Inc. – GETTEX:YAG - TradingView
Mammoth Energy sets March 6 call to review full-year 2025 results - Stock Titan
Atossa Therapeutics Maintains Strong Market Position for (Z)-End - GuruFocus
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program - Sahm
Congress extends $150M FDA voucher program for rare DMD drug - Stock Titan
ATOS stock tumbles 32% — here’s what retail investors think of the reverse stock split - MSN
Atossa Genetics (NASDAQ:ATOS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):